Using ApoE2 to improve brain health in Alzheimer's patients
Reshaping ApoE4 and Alzheimer's Brains with ApoE2
This study is looking at how a special protein called ApoE2 might help protect and treat people with Alzheimer's disease, especially those who are at higher risk because of their genes, by safely delivering it to the brain to boost its health and slow down the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Lawrence NIH-funded |
| Lab location | 1 site (Lawrence, United States) |
| Project ID | NIH-10984453 on NIH RePORTER |
What this research studies
This research investigates how introducing the ApoE2 protein can help protect and treat patients with Alzheimer's disease, particularly those at high risk due to the ApoE4 genotype. The approach involves creating a human-compatible version of the ApoE2 protein and developing a method to deliver it to the brain without invasive procedures. By enhancing brain metabolism and activity, the research aims to slow down the progression of Alzheimer's and improve overall brain function.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, particularly those who carry the ApoE4 allele.
Not a fit: Patients with Alzheimer's disease who do not carry the ApoE4 allele may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve brain health and quality of life for Alzheimer's patients.
How similar studies have performed: Previous research has shown promise in using genetic and protein-based therapies for neurodegenerative diseases, suggesting potential for success in this novel approach.
Where this research is happening
Lawrence, United States
- University of Kansas Lawrence — Lawrence, United States (Active)
Researchers
- Principal investigator: Zhao, Liqin — University of Kansas Lawrence
- Study coordinator: Zhao, Liqin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.